Table 1. Neoadjuvant chemotherapy (NAC) trials that are practice-changing.

	CREATE-X Trial Masuda et al. (2017)54	Katherine Trial von Minckwitz et al. (2019)58
Number of patients randomized	910	1486
Breast cancer subtype	HER2-negative	HER2-positive
Neoadjuvant therapy	Anthracycline, taxane, or both	Taxane (with or without anthracycline) and trastuzumab
Eligibility*	No complete response (CR) on pathological assessment or a CR with positive lymph nodes	Residual invasive disease in the breast or axilla at surgery
Adjuvant therapy	Capecitabine vs. nothing; standard endocrine therapy for hormone receptor positive cancer	Trastuzumab emtansine vs. trastuzumab; standard endocrine therapy for hormone receptor positive cancer
Disease-free survival	At 5 years: 74.1% vs. 67.6%	At 3 years: 88.3% vs. 77.0%
Overall survival	At 5 years: 89.2% vs. 83.6%	To be reported.

*Eligibility assessed after neoadjuvant therapy.